Parma international protocol: Pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation

T. Philip, F. Chauvin, J. Armitage, D. Bron, A. Hagenbeek, P. Biron, G. Spitzer, W. Velasquez, D. D. Weisenburger, J. Fernandez-Ranada, R. Somers, V. Rizzoli, J. L. Harousseau, J. J. Sotto, J. Y. Cahn, F. Guilhot, J. Biggs, P. Sonneveld, J. L. Misset

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

Fifty patients with intermediate- or high-grade non-Hodgkin's lymphoma (NHL) who had relapsed after a complete remission induced by an Adriamycin-containing chemotherapy regimen participated in this prospective pilot study. The patients ranged in age from 16 to 60 years (median 42 years). All patients received dexamethasone, high-dose cytarabine, and cisplatin (DHAP) for two courses at 3- to 4-week intervals. Patients achieving a partial or complete response were scheduled to receive involved-field radiotherapy and high-dose carmustine, etoposide, cytarabine, and cyclophosphamide (BEAC), followed by autologous bone marrow transplantation (ABMT). Among 48 evaluable patients (ie, 1 was lost to follow-up and 1 had no measurable disease) 7 patients obtained a complete response (CR) and another 21 patients achieved partial response (PR), whereas the remaining 20 patients failed. One responder died of treatment-related toxicity, and six others declined ABMT. The patient with no measurable disease did not progress on DHAP and was submitted to ABMT. Twenty-two patients underwent ABMT [20 with BEAC and 2 with cyclophosphamide plus total body irradiation (TBI)] of whom 2 (9%) died of toxicity and 10 relapsed. One patient was a suicide at 28 months post-ABMT in CCR and 9 are alive disease-free 24 months to 32 months (median 30 months) post-ABMT. The actuarial 2-year event-free survival for patients undergoing transplantation is 40%. This prospective multicenter trial documents the ability of DHAP followed by ABMT to produce durable complete remission in a significant proportion of patients with relapsed aggressive NHL. Forty-four percent of all patients with relapsed lymphoma who entered the study actually underwent ABMT and 20% of the total group are projected to be long-term disease-free survivors.

Original languageEnglish (US)
Pages (from-to)1587-1592
Number of pages6
JournalBlood
Volume77
Issue number7
StatePublished - Jan 1 1991
Externally publishedYes

Fingerprint

Autologous Transplantation
Radiotherapy
Bone Marrow Transplantation
Bone
Cytarabine
Cyclophosphamide
Toxicity
Non-Hodgkin's Lymphoma
Carmustine
Chemotherapy
Etoposide
Doxorubicin
Dexamethasone
Cisplatin
Dosimetry
Irradiation
Aptitude
Whole-Body Irradiation
Lost to Follow-Up
Suicide

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Philip, T., Chauvin, F., Armitage, J., Bron, D., Hagenbeek, A., Biron, P., ... Misset, J. L. (1991). Parma international protocol: Pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation. Blood, 77(7), 1587-1592.

Parma international protocol : Pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation. / Philip, T.; Chauvin, F.; Armitage, J.; Bron, D.; Hagenbeek, A.; Biron, P.; Spitzer, G.; Velasquez, W.; Weisenburger, D. D.; Fernandez-Ranada, J.; Somers, R.; Rizzoli, V.; Harousseau, J. L.; Sotto, J. J.; Cahn, J. Y.; Guilhot, F.; Biggs, J.; Sonneveld, P.; Misset, J. L.

In: Blood, Vol. 77, No. 7, 01.01.1991, p. 1587-1592.

Research output: Contribution to journalArticle

Philip, T, Chauvin, F, Armitage, J, Bron, D, Hagenbeek, A, Biron, P, Spitzer, G, Velasquez, W, Weisenburger, DD, Fernandez-Ranada, J, Somers, R, Rizzoli, V, Harousseau, JL, Sotto, JJ, Cahn, JY, Guilhot, F, Biggs, J, Sonneveld, P & Misset, JL 1991, 'Parma international protocol: Pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation', Blood, vol. 77, no. 7, pp. 1587-1592.
Philip, T. ; Chauvin, F. ; Armitage, J. ; Bron, D. ; Hagenbeek, A. ; Biron, P. ; Spitzer, G. ; Velasquez, W. ; Weisenburger, D. D. ; Fernandez-Ranada, J. ; Somers, R. ; Rizzoli, V. ; Harousseau, J. L. ; Sotto, J. J. ; Cahn, J. Y. ; Guilhot, F. ; Biggs, J. ; Sonneveld, P. ; Misset, J. L. / Parma international protocol : Pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation. In: Blood. 1991 ; Vol. 77, No. 7. pp. 1587-1592.
@article{0ead27d4c9af450a90a897892526812d,
title = "Parma international protocol: Pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation",
abstract = "Fifty patients with intermediate- or high-grade non-Hodgkin's lymphoma (NHL) who had relapsed after a complete remission induced by an Adriamycin-containing chemotherapy regimen participated in this prospective pilot study. The patients ranged in age from 16 to 60 years (median 42 years). All patients received dexamethasone, high-dose cytarabine, and cisplatin (DHAP) for two courses at 3- to 4-week intervals. Patients achieving a partial or complete response were scheduled to receive involved-field radiotherapy and high-dose carmustine, etoposide, cytarabine, and cyclophosphamide (BEAC), followed by autologous bone marrow transplantation (ABMT). Among 48 evaluable patients (ie, 1 was lost to follow-up and 1 had no measurable disease) 7 patients obtained a complete response (CR) and another 21 patients achieved partial response (PR), whereas the remaining 20 patients failed. One responder died of treatment-related toxicity, and six others declined ABMT. The patient with no measurable disease did not progress on DHAP and was submitted to ABMT. Twenty-two patients underwent ABMT [20 with BEAC and 2 with cyclophosphamide plus total body irradiation (TBI)] of whom 2 (9{\%}) died of toxicity and 10 relapsed. One patient was a suicide at 28 months post-ABMT in CCR and 9 are alive disease-free 24 months to 32 months (median 30 months) post-ABMT. The actuarial 2-year event-free survival for patients undergoing transplantation is 40{\%}. This prospective multicenter trial documents the ability of DHAP followed by ABMT to produce durable complete remission in a significant proportion of patients with relapsed aggressive NHL. Forty-four percent of all patients with relapsed lymphoma who entered the study actually underwent ABMT and 20{\%} of the total group are projected to be long-term disease-free survivors.",
author = "T. Philip and F. Chauvin and J. Armitage and D. Bron and A. Hagenbeek and P. Biron and G. Spitzer and W. Velasquez and Weisenburger, {D. D.} and J. Fernandez-Ranada and R. Somers and V. Rizzoli and Harousseau, {J. L.} and Sotto, {J. J.} and Cahn, {J. Y.} and F. Guilhot and J. Biggs and P. Sonneveld and Misset, {J. L.}",
year = "1991",
month = "1",
day = "1",
language = "English (US)",
volume = "77",
pages = "1587--1592",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "7",

}

TY - JOUR

T1 - Parma international protocol

T2 - Pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation

AU - Philip, T.

AU - Chauvin, F.

AU - Armitage, J.

AU - Bron, D.

AU - Hagenbeek, A.

AU - Biron, P.

AU - Spitzer, G.

AU - Velasquez, W.

AU - Weisenburger, D. D.

AU - Fernandez-Ranada, J.

AU - Somers, R.

AU - Rizzoli, V.

AU - Harousseau, J. L.

AU - Sotto, J. J.

AU - Cahn, J. Y.

AU - Guilhot, F.

AU - Biggs, J.

AU - Sonneveld, P.

AU - Misset, J. L.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - Fifty patients with intermediate- or high-grade non-Hodgkin's lymphoma (NHL) who had relapsed after a complete remission induced by an Adriamycin-containing chemotherapy regimen participated in this prospective pilot study. The patients ranged in age from 16 to 60 years (median 42 years). All patients received dexamethasone, high-dose cytarabine, and cisplatin (DHAP) for two courses at 3- to 4-week intervals. Patients achieving a partial or complete response were scheduled to receive involved-field radiotherapy and high-dose carmustine, etoposide, cytarabine, and cyclophosphamide (BEAC), followed by autologous bone marrow transplantation (ABMT). Among 48 evaluable patients (ie, 1 was lost to follow-up and 1 had no measurable disease) 7 patients obtained a complete response (CR) and another 21 patients achieved partial response (PR), whereas the remaining 20 patients failed. One responder died of treatment-related toxicity, and six others declined ABMT. The patient with no measurable disease did not progress on DHAP and was submitted to ABMT. Twenty-two patients underwent ABMT [20 with BEAC and 2 with cyclophosphamide plus total body irradiation (TBI)] of whom 2 (9%) died of toxicity and 10 relapsed. One patient was a suicide at 28 months post-ABMT in CCR and 9 are alive disease-free 24 months to 32 months (median 30 months) post-ABMT. The actuarial 2-year event-free survival for patients undergoing transplantation is 40%. This prospective multicenter trial documents the ability of DHAP followed by ABMT to produce durable complete remission in a significant proportion of patients with relapsed aggressive NHL. Forty-four percent of all patients with relapsed lymphoma who entered the study actually underwent ABMT and 20% of the total group are projected to be long-term disease-free survivors.

AB - Fifty patients with intermediate- or high-grade non-Hodgkin's lymphoma (NHL) who had relapsed after a complete remission induced by an Adriamycin-containing chemotherapy regimen participated in this prospective pilot study. The patients ranged in age from 16 to 60 years (median 42 years). All patients received dexamethasone, high-dose cytarabine, and cisplatin (DHAP) for two courses at 3- to 4-week intervals. Patients achieving a partial or complete response were scheduled to receive involved-field radiotherapy and high-dose carmustine, etoposide, cytarabine, and cyclophosphamide (BEAC), followed by autologous bone marrow transplantation (ABMT). Among 48 evaluable patients (ie, 1 was lost to follow-up and 1 had no measurable disease) 7 patients obtained a complete response (CR) and another 21 patients achieved partial response (PR), whereas the remaining 20 patients failed. One responder died of treatment-related toxicity, and six others declined ABMT. The patient with no measurable disease did not progress on DHAP and was submitted to ABMT. Twenty-two patients underwent ABMT [20 with BEAC and 2 with cyclophosphamide plus total body irradiation (TBI)] of whom 2 (9%) died of toxicity and 10 relapsed. One patient was a suicide at 28 months post-ABMT in CCR and 9 are alive disease-free 24 months to 32 months (median 30 months) post-ABMT. The actuarial 2-year event-free survival for patients undergoing transplantation is 40%. This prospective multicenter trial documents the ability of DHAP followed by ABMT to produce durable complete remission in a significant proportion of patients with relapsed aggressive NHL. Forty-four percent of all patients with relapsed lymphoma who entered the study actually underwent ABMT and 20% of the total group are projected to be long-term disease-free survivors.

UR - http://www.scopus.com/inward/record.url?scp=0025896583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025896583&partnerID=8YFLogxK

M3 - Article

C2 - 2009374

AN - SCOPUS:0025896583

VL - 77

SP - 1587

EP - 1592

JO - Blood

JF - Blood

SN - 0006-4971

IS - 7

ER -